TY - JOUR
T1 - Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study
AU - Bar-Oz, Benjamin
AU - Clementi, Maurizio
AU - Di Giantonio, Elena
AU - Greenberg, Revital
AU - Beer, Monic
AU - Merlob, Paul
AU - Arnon, Judy
AU - Ornoy, Asher
AU - Zimmerman, Deena M.
AU - Berkovitch, Matitiahu
PY - 2005/4/1
Y1 - 2005/4/1
N2 - Aim: To assess the teratogenic effect of metamizol when used during the first trimester of pregnancy. Methods: One hundred and eight women who used metamizol during the first trimester of pregnancy were recruited from 4 teratogen information centers in Israel (3) and in Italy (1). The study group was paired for age, smoking habits and alcohol consumption with a comparative group exposed to acetaminophen. Results: Maternal demographics and history, birth weight, gestational age at delivery, rate of live births, spontaneous abortions and fetal distress were comparable in both groups. The rate of major malformations in the metamizol group (3%) did not differ significantly from the rate in the comparative group (2%) (P = 0.57, relative risk = 1.55, 95% confidence interval 0.26-9.05). Conclusions: Our data may suggest that exposure to metamizol during the first trimester of pregnancy is probably not associated with a significantly increased risk for malformations or spontaneous abortions.
AB - Aim: To assess the teratogenic effect of metamizol when used during the first trimester of pregnancy. Methods: One hundred and eight women who used metamizol during the first trimester of pregnancy were recruited from 4 teratogen information centers in Israel (3) and in Italy (1). The study group was paired for age, smoking habits and alcohol consumption with a comparative group exposed to acetaminophen. Results: Maternal demographics and history, birth weight, gestational age at delivery, rate of live births, spontaneous abortions and fetal distress were comparable in both groups. The rate of major malformations in the metamizol group (3%) did not differ significantly from the rate in the comparative group (2%) (P = 0.57, relative risk = 1.55, 95% confidence interval 0.26-9.05). Conclusions: Our data may suggest that exposure to metamizol during the first trimester of pregnancy is probably not associated with a significantly increased risk for malformations or spontaneous abortions.
KW - Congenital malformations
KW - Metamizol
KW - Pregnancy
KW - Teratogenic effect
UR - http://www.scopus.com/inward/record.url?scp=20144388116&partnerID=8YFLogxK
U2 - 10.1016/j.ejogrb.2004.07.004
DO - 10.1016/j.ejogrb.2004.07.004
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15808375
AN - SCOPUS:20144388116
SN - 0301-2115
VL - 119
SP - 176
EP - 179
JO - European Journal of Obstetrics, Gynecology and Reproductive Biology
JF - European Journal of Obstetrics, Gynecology and Reproductive Biology
IS - 2
ER -